Impact of Sunitinib Bioavailability on Toxicity and Treatment Efficacy in Patients Treated for Metastatic Renal Cancer

NCT03846128 · clinicaltrials.gov ↗
TERMINATED
Status
6
Enrollment
OTHER
Sponsor class

Stopped Changes in the indication for Sunitinib in metastatic renal cell carcinoma, which have led to a significant decrease in its use in the urology department. Collected data will not be sufficient to perform a statistical analysis.

Conditions

Interventions

Sponsor

University Hospital, Rouen